or Try an Advanced Search...

    Technical Analysis for AVBP - ArriVent BioPharma, Inc.

    Grade Last Price % Change Price Change
    C 27.54 0.47% 0.13
    AVBP closed down 0.04 percent on Wednesday, November 20, 2024, on 40 percent of normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical AVBP trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.47%
    MACD Bearish Centerline Cross Bearish 0.47%
    Wide Bands Range Expansion 0.47%
    Oversold Stochastic Weakness 0.47%
    50 DMA Resistance Bearish 0.44%
    Bullish Engulfing Bullish 0.44%
    Spinning Top Other 0.44%
    Outside Day Range Expansion 0.44%
    Wide Bands Range Expansion 0.44%
    Oversold Stochastic Weakness 0.44%
    Older End-of-Day Signals for AVBP ...

       Recent Intraday Alerts

    Alert Time
    Up 1% 34 minutes ago
    60 Minute Opening Range Breakout 41 minutes ago
    Down 1% about 2 hours ago
    60 Minute Opening Range Breakdown about 2 hours ago
    1.5x Volume Pace about 2 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AVBP Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Solid Tumors Cancer Treatment Non Small Cell Lung Cancer Antineoplastic Drugs Orphan Drug Lung Cancer Protein Kinase Inhibitor Tyrosine Kinase Cancer Therapies NSCLC Bemcentinib

    Is AVBP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
    Nov 14 ArriVent BioPharma Reports Third Quarter 2024 Financial Results
    Sep 17 ArriVent BioPharma: Bringing A Novel Cancer Drug From China
    Sep 9 ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
    Sep 6 We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
    Aug 19 Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
    Aug 14 ArriVent BioPharma Reports Second Quarter 2024 Financial Results
    Aug 12 ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
    Jul 27 ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%
    Jul 22 Oppenheimer starts ArriVent BioPharma at outperform
    See more AVBP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 36.2
    52 Week Low 14.35
    Average Volume 242,397
    200-Day Moving Average 21.93
    50-Day Moving Average 28.04
    20-Day Moving Average 31.11
    10-Day Moving Average 30.62
    Average True Range 1.77
    RSI (14) 40.12
    ADX 27.09
    +DI 22.04
    -DI 30.81
    Chandelier Exit (Long, 3 ATRs) 30.89
    Chandelier Exit (Short, 3 ATRs) 31.71
    Upper Bollinger Bands 36.26
    Lower Bollinger Band 25.96
    Percent B (%b) 0.14
    BandWidth 33.12
    MACD Line -0.17
    MACD Signal Line 0.74
    MACD Histogram -0.906
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 29.74
    Resistance 3 (R3) 29.95 29.38 29.35
    Resistance 2 (R2) 29.38 28.79 29.28 29.22
    Resistance 1 (R1) 28.40 28.43 28.12 28.19 29.09
    Pivot Point 27.83 27.83 27.69 27.73 27.83
    Support 1 (S1) 26.85 27.24 26.57 26.64 25.73
    Support 2 (S2) 26.28 26.88 26.18 25.60
    Support 3 (S3) 25.30 26.28 25.47
    Support 4 (S4) 25.09